Privia Health Group, Inc. (PRVA)
NEUTRALFundamental
62
Precio
$21.03
Capitalización Bursátil
$2.70B
Parte 1 · Cuánto vale la empresa
Resumen
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$2.36B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$28M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
-
Patrimonio Neto Total
$737M
Pasivo Total
$578M
Ratio de Liquidez
1.62
Cobertura de Intereses
-
Deuda/EBITDA
0.20
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$19.19
Precio Actual
$21.03
Margen de Seguridad
-9.6%
Rango de Valor Justo
$12.47 - $25.90
Métodos de Estimación
Métricas de Valoración
Ratio P/E
95.55
ROE
3.1%
Ratio P/B
3.43
P/FCF
-
Margen Bruto
-
ROIC
4.2%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
4.2%
WACC
8.9%
ROIC − WACC
-4.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (13)
- EPS shows upward trend
- EPS CAGR 12.25%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 21.0%
- Analyst Consensus 88% Buy
- Earnings Surprise avg 3.9%
- Earnings Quality (OCF/NI) 4.66
- Share Dilution -2.6%
- Net Margin Trend 1.2% vs 0.8%
- Piotroski F-Score 6/9
Fallido (8)
- Price CAGR -3.98%
- ROIC 4.2%
- P/B Ratio 3.43
- Operating Margin 1.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
No disponible (7)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Parth Mehrotra | CEO & Director | 46 |
| Mr. David Mountcastle CPA, MBA | Executive VP & CFO | 55 |
| Mr. Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 60 |
| Mr. Sarath Degala | Chief Operating Officer | - |
| Mr. Konda Mullapudi | Executive VP & CTO | - |
| Mr. Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | - |
| Ms. Dana Fields CPA | Chief Audit & Compliance Officer | - |
| Ms. Jenny Harding | Chief People Officer | - |
| Mr. Jay Stevens | Senior VP & Chief Growth Officer | - |
| Mr. Eric J. Beyer | Executive Vice President of Medical Groups | - |
Riesgo de Auditoría
1
Riesgo del Consejo
2
Riesgo de Compensación
3
Riesgo de Derechos del Accionista
6
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for PRVA, sourced from Markets Gazette.
- 2/26/2026NEUTRALPrivia Health (PRVA) Q4 2025 Earnings Transcript
The financial market is currently awaiting the detailed transcript of Privia Health's (PRVA) Q4 2025 earnings call. While the specific content remains unavailable, investors will be keenly scrutinizing this document for clarity on the company's financial health and future trajectory. Earnings transcripts are vital as they provide direct insights from management discussions, detailing revenues, profits, operating margins, and crucially, future guidance. The current lack of concrete data keeps the stock in a state of anticipation, with market participants looking for signals regarding patient growth, geographical expansion, and cost management strategies. The stock's reaction will heavily depend on the tone and figures revealed once the full transcript is released.
via Markets Gazette